Current treatment guidelines for severe symptomatic chronic hyponatremia recommend empiric intervention with intravenous 3% NaCl to increase serum sodium levels by 46 mmol/L within the first 24 h 3,4,6,7,8,9
Preclinical studies showed lipolytic and anti-lipogenic effects, but human trials failed to demonstrate significant weight-loss outcomes
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
During the therapy, BPC-157 is administered through injections or oral capsules
Whether you are just beginning or have been trying various methods without success, our clinic offers a range of effective weight loss treatments tailored to your individual needs
[DOI] [PMC free article] [PubMed] [Google Scholar] References to other published versions of this review VidalAlaball 2005 VidalAlaball J, Butler CC, CanningsJohn R, Goringe A, Hood K, McCaddon A, et al
